GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (NAS:REVB) » Definitions » EV-to-Revenue

REVB (Revelation Biosciences) EV-to-Revenue : (As of May. 28, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Revelation Biosciences's enterprise value is $-1.52 Mil. Revelation Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil. Therefore, Revelation Biosciences's EV-to-Revenue for today is .

The historical rank and industry rank for Revelation Biosciences's EV-to-Revenue or its related term are showing as below:

REVB's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.38
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-28), Revelation Biosciences's stock price is $1.93. Revelation Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00. Therefore, Revelation Biosciences's PS Ratio for today is .


Revelation Biosciences EV-to-Revenue Historical Data

The historical data trend for Revelation Biosciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences EV-to-Revenue Chart

Revelation Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
- - - - -

Revelation Biosciences Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Revelation Biosciences's EV-to-Revenue

For the Biotechnology subindustry, Revelation Biosciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revelation Biosciences's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revelation Biosciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Revelation Biosciences's EV-to-Revenue falls into.


;
;

Revelation Biosciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Revelation Biosciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-1.517/0
=

Revelation Biosciences's current Enterprise Value is $-1.52 Mil.
Revelation Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revelation Biosciences  (NAS:REVB) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Revelation Biosciences's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.93/0
=

Revelation Biosciences's share price for today is $1.93.
Revelation Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revelation Biosciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Revelation Biosciences Business Description

Traded in Other Exchanges
N/A
Address
4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
Executives
George F Tidmarsh director, 10 percent owner
Lakhmir S Chawla director 1960 KIRBY ROAD, MCLEAN VA 22101
Axa Im Prime Impact Gp S.a.r.l other: Former 10% owner 2-4, RUE EUGENE RUPPERT, LUXEMBOURG N4 L-2453
Axa Im Prime Impact Master Fund I Sca Sicav-raif other: Former 10% Owner 2-4 RUE EUGENE RUPPERT, LUXEMBOURG N4 L-2453
Axa Investment Managers S.a. other: Former 10% owner 6 PLACE DE LA PYRAMIDE, TOUR MAJUNGA, PUTEAUX I0 92800
Axa Investment Managers Paris other: Former 10% owner 6 PLACE DE LA PYRAMIDE, PUTEAUX I0 92800
Axa Investment Managers Uk Ltd other: Former 10% owner 22 BISHOPGATE, LONDON X0 EC2M 3XJ
S.a. Axa other: Former 10% owner 25 AVENUE MATIGNON, PARIS I0 75008
Jess Roper director 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
James Rolke director, officer: Chief Executive Officer 10182 TELESIS COURT, 6TH FLOOR, SAN DIEGO CA 92121
Curt H Labelle director C/O INVESTOR GROWTH CAPITAL, INC., 630 FIFTH AVENUE, SUITE 1965, NEW YORK NY 10011
Jennifer Carver director 725 NEWPORT STREET, DENVER CO 80220
Zygmont Chester Stanley Iii officer: Chief Financial Officer 3322 MILLIKIN AVE, SAN DIEGO CA 92122
Lawrence Feis 10 percent owner 190 EAST WALTON PLACE, UNIT 603, CHICAGO IL 60611
Feis Equities Llc 10 percent owner 20 NORTH WACKER DRIVE, SUITE 2115, CHICAGO IL 60606